Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker Study for Finerenone in Diabetic Kidney Disease (FIGARO-BM)
NCT05013008Phase 2Completed
- Sponsor
- Bayer
- Start
- Aug 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 21
01
Overview
Phase 2, open-label trial of finerenone in diabetic kidney disease (DKD) (2 arms), sponsored by Bayer. Primary endpoint: Mean Change in Plasma Biomarker Levels at 36 months. Started Aug 2021; status: completed.
02
Drugs
finerenone
03
Conditions
diabetic kidney disease (DKD)
Beyond the preview
Go deeper on NCT05013008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05013008.